Reactivity: Mouse, Rat, Human
This EIA kit is used for quantitative determination of rat, mouse or human pancreatic glucagon in plasma sample. The kit is characterized for sensitive quantification, high specificity and no influence with other components in plasma and needlessness of sample pre-treatment. Glucagon standard used in the kit system is highly purified synthetic product (purity: higher than 98%) and biotinylated pancreatic glucagon is purified by HPLC. Supplementary: Competitive
Applicable Sample: Plasma
Other: According to many studies on glucagon immunoassay, it has been established that the antibody against the C-terminal fragment (19-29) of glucagon has specific binding with pancreaticglucagon, whereas the antibody against the N - terminal fragment (1-19) of glucagon has specific binding with both of pancreatic and intestinal glucagon (total glucagon). Once, 30K by Unger et. al had been widely used as an antibody specific for theC- terminal fragment of glucagon, but Nishino, Shima and Yanaihara et. al succeeded in producing pancreatic glucagon specific antibody using synthetic peptide with the Cterminal fragment (19-29) of glucagon as immunogen in 1981. This EIA kit has beendeveloped by using polyclonal antibody against glucagons (19-29), synthetic pancreatic glucagon as glucagon standard and biotinylated pancreatic glucagon as labeled antigen for the measurement of rat, mouse or human glucagon in plasma.
This EIA kit is used for quantitative determination of rat, mouse or human pancreatic glucagon in plasma sample. The kit is characterized for sensitive quantification, high specificity and no influence with other components in plasma and needlessness of sample pre-treatment. Glucagon standard used in the kit system is highly purified synthetic product (purity: higher than 98%) and biotinylated pancreatic glucagon is purified by HPLC. Supplementary: Competitive
Applicable Sample: Plasma
Other: According to many studies on glucagon immunoassay, it has been established that the antibody against the C-terminal fragment (19-29) of glucagon has specific binding with pancreaticglucagon, whereas the antibody against the N - terminal fragment (1-19) of glucagon has specific binding with both of pancreatic and intestinal glucagon (total glucagon). Once, 30K by Unger et. al had been widely used as an antibody specific for theC- terminal fragment of glucagon, but Nishino, Shima and Yanaihara et. al succeeded in producing pancreatic glucagon specific antibody using synthetic peptide with the Cterminal fragment (19-29) of glucagon as immunogen in 1981. This EIA kit has beendeveloped by using polyclonal antibody against glucagons (19-29), synthetic pancreatic glucagon as glucagon standard and biotinylated pancreatic glucagon as labeled antigen for the measurement of rat, mouse or human glucagon in plasma.
| Documents & Links for Glucagon EIA | |
| Datasheet | yii-yk090-ex_glucagon-eia_datasheet.pdf |
| Vendor Page | Glucagon EIA at Cosmo Bio LTD |
| Documents & Links for Glucagon EIA | |
| Datasheet | yii-yk090-ex_glucagon-eia_datasheet.pdf |
| Vendor Page | Glucagon EIA |
| Citations for Glucagon EIA – 3 Found |
| Fast/Glycolytic muscle fiber growth reduces fat mass and improves metabolic parameters in obese mice. Cell Metab. 2008 Feb;7(2):159-72. doi: 10.1016/j.cmet.2007.11.003. PubMed |
| Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis. J Pharmacol Exp Ther. 2010 Aug;334(2):430-8. doi: 10.1124/jpet.110.167544. Epub 2010 May 3. PubMed |
| Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. J Hepatol. 2011 Jun;54(6):1214-23. doi: 10.1016/j.jhep.2010.09.032. Epub 2010 Oct 26. PubMed |